🧩 Diagnostic Reasoning Exercise / Teaching Case
A 4-year-old with a known inherited tumor-predisposition syndrome develops reproducible unilateral visual-acuity decline, a relative afferent pupillary defect, and optic disc pallor during routine surveillance. MRI demonstrates optic nerve enlargement extending into the chiasm without hydrocephalus. After systemic chemotherapy stabilizes vision and modestly reduces tumor size, bilateral visual deterioration recurs 14 months later. Optical coherence tomography shows new retinal nerve fiber layer thinning, while MRI demonstrates chiasmatic progression toward the contralateral optic nerve.
Diagnostic Considerations
- Reproducible visual decline, rather than radiographic enlargement alone, represents the principal clinical signal requiring treatment reassessment.
- Typical imaging in the setting of a known predisposition syndrome may establish the working diagnosis without high-risk tissue sampling.
- Bilateral acuity deterioration and new retinal nerve fiber layer thinning suggest clinically meaningful progression rather than isolated imaging change.
- Radiographic and functional responses may diverge, making serial quantitative ophthalmologic assessment essential throughout treatment and surveillance.
- Prior therapy, current visual trajectory, tumor behavior, and treatment-specific eligibility should guide selection of the next systemic approach.
- The case requires balancing irreversible visual injury against cardiac, ophthalmologic, muscular, and other toxicities associated with targeted treatment.
Practice Pearls
- Prioritize reproducible visual function and optical coherence tomography findings when evaluating apparent progression.
- Avoid delaying reassessment when bilateral visual deterioration indicates potential irreversible optic pathway injury.
- Integrate neuro-oncology, ophthalmology, cardiology, and laboratory monitoring when targeted systemic therapy is considered.
- Monitor vision and imaging separately because anatomic response may not predict functional benefit.
- Discuss treatment duration uncertainty and post-discontinuation surveillance with families before initiating prolonged therapy.
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS